AB
Andrew Booth bought $384K of ABCL stock
Andrew Booth, Chief Financial Officer of AbCellera Biologics Inc. (ABCL), bought 37,200 shares of ABCL stock worth $384K, per an SEC Form 4 filed Aug 14, 2026.
It was an open-market purchase.
The trade was reported on Aug 14, 2026.
ABCL has moved +1.0% since the trade date, from $11.38 to $11.49 (Nov 13, 2026 close).
- Traded
- Aug 14, 2026
- Disclosed
- Aug 14, 2026
- Filing delay
- 0 days
- Price since
- +1.0%
- Role
- Chief Financial Officer
- Source
- SEC Form 4